Problemi di apprendimento di tre perifrasi fra spagnolo e italiano. Osservazioni acquisizionali e proposte pedagogiche.

Il contributo prende in considerazione alcuni problemi acquisizionali particolarmente ostici e persistenti nel processo di apprendimento dell’italiano da parte di discenti ispanofoni. Sono noti, in letteratura, i fenomeni di transfer additivo e persistente di strutture perifrastiche spagnole non presenti in italiano. È il caso di "andare/venire + gerundio", strutture “gemelle” di "ir/venir + gerundio": contemplate e frequenti, in spagnolo, in contesti diafasici anche bassi e trascurati, tali perifrasi, in italiano standard e neo standard, hanno perso molto “spazio” d’uso, e sono oggi relegate a varietà diafasiche molto alte della lingua. Per "estar + gerundio" e "stare + gerundio" – la terza coppia di perifrasi considerate in questo studio –, notiamo invece, in italiano, severe restrizioni aspettuali: "estar + gerundio" esprime sia l’aspetto progressivo che quello continuativo, mentre "stare + gerundio" si è specializzata solo nell’aspetto progressivo. Ne conseguono fenomeni di transfer spagnolo-italiano tipici, ben rintracciabili in realizzazioni come "*sono stato lavorando tutta la notte". L’interpretazione psicolinguistica di tali problemi acquisizionali è basata sulla difficoltà di individuazione delle prove che possano permettere la ristrutturazione dell’interlingua: in questi tre casi sono prove negative indirette, ovvero la non apparenza delle strutture in determinati contesti o incongruenza con determinati valori aspettuali. Per lenire i problemi di transfer additivo delle tre perifrasi, in questo lavoro, dopo aver approfondito gli aspetti psicolinguistici di cui sopra, considereremo se e come le grammatiche pedagogiche di italiano per stranieri – in particolar modo ispanofoni – trattano queste discrepanze fra le due lingue. Proporremo infine alcuni accorgimenti pedagogici che possono essere utili per aiutare i discenti ispanofoni ad analizzare correttamente l’input italiano, così da lenire l’interferenza negativa fra le due lingue

Noninvasive vagus nerve stimulation as acute therapy for migraine. The randomized PRESTO study

Objective: To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine in a multicenter, double-blind, randomized, sham-controlled trial. Methods: A total of 248 participants with episodic migraine with/without aura were randomized to receive nVNS or sham within 20 minutes from pain onset. Participants were to repeat treatment if pain had not improved in 15 minutes. Results: nVNS (n = 120) was superior to sham (n = 123) for pain freedom at 30 minutes (12.7% vs 4.2%; p = 0.012) and 60 minutes (21.0% vs 10.0%; p = 0.023) but not at 120 minutes (30.4% vs 19.7%; p = 0.067; primary endpoint; logistic regression) after the first treated attack. A post hoc repeatedmeasures test provided further insight into the therapeutic benefit of nVNS through 30, 60, and 120 minutes (odds ratio 2.3; 95% confidence interval 1.2, 4.4; p = 0.012). nVNS demonstrated benefits across other endpoints including pain relief at 120minutes and was safe and well-tolerated. Conclusion: This randomized sham-controlled trial supports the abortive efficacy of nVNS as early as 30 minutes and up to 60 minutes after an attack. Findings also suggest effective pain relief, tolerability, and practicality of nVNS for the acute treatment of episodic migraine

On the importance of anandamide structural features for its interactions with DPPC bilayers: effects on PLA2 activity

The acylethanolamide anandamide (AEA) occurs in a variety of mammalian tissues and, as a result of its action on cannabinoid receptors, exhibits several cannabimimetic activities. Moreover, some of its effects are mediated through interaction with an ion channel-type vanilloid receptor. However, the chemical features of AEA suggest that some of its biological effects could be related to physical interactions with the lipidic part of the membrane. The present work studies the effect of AEA-induced structural modifications of the dipalmitoylphosphatidylcholine (DPPC) bilayer on phospholipase A2 (PLA2) activity, which is strictly dependent on lipid bilayer features. This study, performed by 2-dimethylamino-(6-lauroyl)-naphthalene fluorescence, demonstrates that the effect of AEA on PLA2 activity is concentration-dependent. In fact, at low AEA/DPPC molar ratios (from R = 0.001 to R = 0.04), there is an increase of the enzymatic activity, which is completely inhibited for R = 0.1. X-ray diffraction data indicate that the AEA affects DPPC membrane structural properties in a concentration-dependent manner. Because the biphasic effect of increasing AEA concentrations on PLA2 activity is related to the induced modifications of membrane bilayer structural properties, we suggest that AEA-phospholipid interactions may be important to produce, at least in part, some of the similarly biphasic responses of some physiological activities to increasing concentrations of AEA

Minimally invasive video-assisted thyroidectomy (MIVAT)

Minimally invasive video-assisted thyroidectomy (MIVAT) was first described in 1999 and it has become a widespread technique performed worldwide. Although initially limited to benign thyroid nodules, MIVAT was progressively adopted for all types of thyroid diseases, while remaining within the selection criteria. It is reported that, in selected cases, MIVAT is comparable to standard open thyroidectomy (SOT) in terms of oncologic radicality, time, costs and complications rate, with the advantage of a better cosmetic result and a lower post-operative pain

Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: A post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Background: The PRESTO study of non-invasive vagus nerve stimulation (nVNS; gammaCore\uae) featured key primary and secondary end points recommended by the International Headache Society to provide Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 h post stimulation. Here, we examined additional data from PRESTO to provide further insights into the practical utility of nVNS by evaluating its ability to consistently deliver clinically meaningful improvements in pain intensity while reducing the need for rescue medication. Methods: Patients recorded pain intensity for treated migraine attacks on a 4-point scale. Data were examined to compare nVNS and sham with regard to the percentage of patients who benefited by at least 1 point in pain intensity. We also assessed the percentage of attacks that required rescue medication and pain-free rates stratified by pain intensity at treatment initiation. Results: A significantly higher percentage of patients who used acute nVNS treatment (n = 120) vs sham (n = 123) reported a 65 1-point decrease in pain intensity at 30 min (nVNS, 32.2%; sham, 18.5%; P = 0.020), 60 min (nVNS, 38.8%; sham, 24.0%; P = 0.017), and 120 min (nVNS, 46.8%; sham, 26.2%; P = 0.002) after the first attack. Similar significant results were seen when assessing the benefit in all attacks. The proportion of patients who did not require rescue medication was significantly higher with nVNS than with sham for the first attack (nVNS, 59.3%; sham, 41.9%; P = 0.013) and all attacks (nVNS, 52.3%; sham, 37.3%; P = 0.008). When initial pain intensity was mild, the percentage of patients with no pain after treatment was significantly higher with nVNS than with sham at 60 min (all attacks: nVNS, 37.0%; sham, 21.2%; P = 0.025) and 120 min (first attack: nVNS, 50.0%; sham, 25.0%; P = 0.018; all attacks: nVNS, 46.7%; sham, 30.1%; P = 0.037). Conclusions: This post hoc analysis demonstrated that acute nVNS treatment quickly and consistently reduced pain intensity while decreasing rescue medication use. These clinical benefits provide guidance in the optimal use of nVNS in everyday practice, which can potentially reduce use of acute pharmacologic medications and their associated adverse events. Trial registration: ClinicalTrials.gov identifier: NCT02686034

11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma

<p>Abstract</p> <p>Background</p> <p>Multiple Myeloma (MM) is a B cell neoplasm causing lytic or osteopenic bone abnormalities. Whole body skeletal survey (WBSS), Magnetic resonance (MR) and ¹⁸F-FDG PET/CT are imaging techniques routinely used for the evaluation of bone involvement in MM patients.</p> <p>Aim</p> <p>As MM bone lesions may present low ¹⁸F-FDG uptake; the aim of this study was to assess the possible added value and limitations of ¹¹C-Choline to that of ¹⁸F-FDG PET/CT in patients affected with MM.</p> <p>Methods</p> <p>Ten patients affected with MM underwent a standard ¹¹C-Choline PET/CT and an ¹⁸F-FDG PET/CT within one week. The results of the two scans were compared in terms of number, sites and SUV_maxof lesions.</p> <p>Results</p> <p>Four patients (40%) had a negative concordant ¹¹C-Choline and ¹⁸F-FDG PET/CT scans. Two patients (20%) had a positive ¹¹C-Choline and ¹⁸F-FDG PET/CT scans that identified the same number and sites of bone lesions. The remaining four patients (40%) had a positive ¹¹C-Choline and ¹⁸F-FDG PET/CT scan, but the two exams identified different number of lesions. Choline showed a mean SUV_maxof 5 while FDG showed a mean SUV_maxof 3.8 (P = 0.042). Overall, ¹¹C-Choline PET/CT scans detected 37 bone lesions and ¹⁸F-FDG PET/CT scans detected 22 bone lesions but the difference was not significant (P = 0.8).</p> <p>Conclusion</p> <p>According to these preliminary data, ¹¹C-Choline PET/CT appears to be more sensitive than ¹⁸F-FDG PET/CT for the detection of bony myelomatous lesions. If these data are confirmed in larger series of patients, ¹¹C-Choline may be considered a more appropriate functional imaging in association with MRI for MM bone staging.</p

Tumor necrosis factor αlpha impairs kisspeptin signaling in human fetal hypothalamic neurons

  Previous studies in both human and animal models have linked overnutrition-related metabolic dysfunctions to hypothalamic inflammation (1, 2). Moreover, metabolic disorders are often associated with male hypogonadotropic hypogonadism, suggesting that inflammatory pathways may impair central regulatory networks involving gonadotropin releasing hormone (GnRH) neuron activity. However, studies in humans are strongly hampered by the anatomical distribution of these neurons, scattered within the preoptic area of the hypothalamus. This study was aimed at investigating the effects of inflammatory stimuli in human fetal hypothalamic (hfHypo) primary cell cultures. These cells have shown evident GnRH neuron features, as demonstrated by quantitative gene expression profile, immunohistochemistry, flow cytometry and ELISA detection of GnRH peptide in the culture medium. Moreover, hfHypo cells express KISS1R and accordingly respond to kisspeptin, the main central regulator of GnRH neuron function. Exposing hfHypo cells to TNFα (10ng/ml, 5h) determined nuclear translocation of NFkB, as well as a significant increase of COX2 mRNA expression, thus demonstrating the induction of inflammatory signaling. Prolonged exposure (24 h) to TNFα strongly down-regulated KISS1R mRNA without changing GnRH expression. Moreover, we know that kisspeptin is able to depolarize GnRH neurons through the activation of a canonical transient receptor potential (TRPC)-like cationic channel. Electrophisiological studies demonstrated that kisspeptin (1 μM) induced a clear TRPC-mediated depolarizing response in hfHypo cells. Pretreating cells with TNFα (10 ng/ml, 24h) significantly inhibited kisspeptin-sensitive TRPC currents. Our results indicate that inflammatory pathways may impair GnRH neuron function by interfering with the ability of these neurons in responding to kisspeptin

Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine. A post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Background: The PRESTO study of non-invasive vagus nerve stimulation (nVNS; gammaCore®) featured key primary and secondary end points recommended by the International Headache Society to provide Class I evidence that for patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-free 2 h post stimulation. Here, we examined additional data from PRESTO to provide further insights into the practical utility of nVNS by evaluating its ability to consistently deliver clinically meaningful improvements in pain intensity while reducing the need for rescue medication. Methods: Patients recorded pain intensity for treated migraine attacks on a 4-point scale. Data were examined to compare nVNS and sham with regard to the percentage of patients who benefited by at least 1 point in pain intensity. We also assessed the percentage of attacks that required rescue medication and pain-free rates stratified by pain intensity at treatment initiation. Results: A significantly higher percentage of patients who used acute nVNS treatment (n = 120) vs sham (n = 123) reported a ≥ 1-point decrease in pain intensity at 30 min (nVNS, 32.2%; sham, 18.5%; P = 0.020), 60 min (nVNS, 38.8%; sham, 24.0%; P = 0.017), and 120 min (nVNS, 46.8%; sham, 26.2%; P = 0.002) after the first attack. Similar significant results were seen when assessing the benefit in all attacks. The proportion of patients who did not require rescue medication was significantly higher with nVNS than with sham for the first attack (nVNS, 59.3%; sham, 41.9%; P = 0.013) and all attacks (nVNS, 52.3%; sham, 37.3%; P = 0.008). When initial pain intensity was mild, the percentage of patients with no pain after treatment was significantly higher with nVNS than with sham at 60 min (all attacks: nVNS, 37.0%; sham, 21.2%; P = 0.025) and 120 min (first attack: nVNS, 50.0%; sham, 25.0%; P = 0.018; all attacks: nVNS, 46.7%; sham, 30.1%; P = 0.037). Conclusions: This post hoc analysis demonstrated that acute nVNS treatment quickly and consistently reduced pain intensity while decreasing rescue medication use. These clinical benefits provide guidance in the optimal use of nVNS in everyday practice, which can potentially reduce use of acute pharmacologic medications and their associated adverse events. Trial registration: ClinicalTrials.gov identifier: NCT02686034